Mostafa NM - Search Results

1

Long-term safety and efficacy of adalimumab in Japanese patients with moderate to severe Crohn's disease.

Watanabe M, Hibi T, Mostafa NM, Chao J, Arora V, Camez A, Petersson J, Thakkar R. Watanabe M, et al. Among authors: mostafa nm. J Crohns Colitis. 2014 Nov;8(11):1407-16. doi: 10.1016/j.crohns.2014.04.012. Epub 2014 May 27. J Crohns Colitis. 2014. PMID: 24874893 Clinical Trial.

2

Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis.

Suzuki Y, Motoya S, Hanai H, Matsumoto T, Hibi T, Robinson AM, Mostafa NM, Chao J, Arora V, Camez A, Thakkar RB, Watanabe M. Suzuki Y, et al. Among authors: mostafa nm. J Gastroenterol. 2014 Feb;49(2):283-94. doi: 10.1007/s00535-013-0922-y. Epub 2013 Dec 24. J Gastroenterol. 2014. PMID: 24363029 Free PMC article. Clinical Trial.

3

Efficacy and Safety of Escalation of Adalimumab Therapy to Weekly Dosing in Pediatric Patients with Crohn's Disease.

Dubinsky MC, Rosh J, Faubion WA Jr, Kierkus J, Ruemmele F, Hyams JS, Eichner S, Li Y, Huang B, Mostafa NM, Lazar A, Thakkar RB. Dubinsky MC, et al. Among authors: mostafa nm. Inflamm Bowel Dis. 2016 Apr;22(4):886-93. doi: 10.1097/MIB.0000000000000715. Inflamm Bowel Dis. 2016. PMID: 26950307 Free PMC article. Clinical Trial.

4

Adalimumab induction and maintenance therapy achieve clinical remission and response in Chinese patients with Crohn's disease.

Wu KC, Ran ZH, Gao X, Chen M, Zhong J, Sheng JQ, Kamm MA, Travis S, Wallace K, Mostafa NM, Shapiro M, Li Y, Thakkar RB, Robinson AM. Wu KC, et al. Among authors: mostafa nm. Intest Res. 2016 Apr;14(2):152-63. doi: 10.5217/ir.2016.14.2.152. Epub 2016 Apr 27. Intest Res. 2016. PMID: 27175116 Free PMC article.

5

Impact of immunogenicity on pharmacokinetics, efficacy and safety of adalimumab in adult patients with moderate to severe chronic plaque psoriasis.

Mostafa NM, Nader AM, Noertersheuser P, Okun M, Awni WM. Mostafa NM, et al. J Eur Acad Dermatol Venereol. 2017 Mar;31(3):490-497. doi: 10.1111/jdv.13884. Epub 2016 Aug 22. J Eur Acad Dermatol Venereol. 2017. PMID: 27545848 Clinical Trial.

6

Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventional therapy.

Colombel JF, Jharap B, Sandborn WJ, Feagan B, Peyrin-Biroulet L, Eichner SF, Robinson AM, Mostafa NM, Zhou Q, Thakkar RB. Colombel JF, et al. Among authors: mostafa nm. Aliment Pharmacol Ther. 2017 Jan;45(1):50-62. doi: 10.1111/apt.13838. Epub 2016 Nov 7. Aliment Pharmacol Ther. 2017. PMID: 27883215 Free PMC article. Clinical Trial.

7

Population Pharmacokinetics and Immunogenicity of Adalimumab in Adult Patients with Moderate-to-Severe Hidradenitis Suppurativa.

Nader A, Beck D, Noertersheuser P, Williams D, Mostafa N. Nader A, et al. Clin Pharmacokinet. 2017 Sep;56(9):1091-1102. doi: 10.1007/s40262-016-0502-4. Clin Pharmacokinet. 2017. PMID: 28066879 Clinical Trial.

8

Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis.

Suzuki Y, Motoya S, Hanai H, Hibi T, Nakamura S, Lazar A, Robinson AM, Skup M, Mostafa NM, Huang B, Thakkar R, Watanabe M. Suzuki Y, et al. Among authors: mostafa nm. J Gastroenterol. 2017 Sep;52(9):1031-1040. doi: 10.1007/s00535-017-1325-2. Epub 2017 Mar 20. J Gastroenterol. 2017. PMID: 28321512 Free PMC article. Clinical Trial.

9

Erratum to: Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis.

Suzuki Y, Motoya S, Hanai H, Hibi T, Nakamura S, Lazar A, Robinson AM, Skup M, Mostafa NM, Huang B, Thakkar R, Watanabe M. Suzuki Y, et al. Among authors: mostafa nm. J Gastroenterol. 2017 Sep;52(9):1079. doi: 10.1007/s00535-017-1340-3. J Gastroenterol. 2017. PMID: 28405767 Free PMC article. No abstract available.

10

Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind study.

Landewé R, Sieper J, Mease P, Inman RD, Lambert RG, Deodhar A, Marzo-Ortega H, Magrey M, Kiltz U, Wang X, Li M, Zhong S, Mostafa NM, Lertratanakul A, Pangan AL, Anderson JK. Landewé R, et al. Among authors: mostafa nm. Lancet. 2018 Jul 14;392(10142):134-144. doi: 10.1016/S0140-6736(18)31362-X. Epub 2018 Jun 29. Lancet. 2018. PMID: 29961640 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

116 results

Search Page

Filters